Literature DB >> 724314

Age-dependent closure of the patent ductus arteriosus by indomethacin.

J S McCarthy, L G Zies, H Gelband.   

Abstract

Indomethacin has been shown to be effective in closing a patient ductus arteriosus (PDA) in small premature infants. However, the age range over which this therapy is effective remains undetermined. Eighteen infants ranging in age from 4 to 45 days were studied. All had auscultatory and clinical findings indicative of PDA. Seventeen had roentgenographic evidence of cardiomegaly and/or increased pulmonary vascular markings, and eight had ECG evidence of ventricular hypertrophy. Indomethacin was administered to most patients in two doses of 0.1 to 0.3 mg/kg 24 hours apart. In eight of 12 patients, 3 week of age or younger, the PDA closed after indomethacin therapy. Two patients had a decrease in the intensity of murmur and improvement of congestive heart failure after treatment, but the PDA did not close completely. Only patients 33 weeks of age (actual age) or younger responded to indomethacin therapy with complete ductal closure. The condition of patients 34 to 36 weeks of age improved but there was not complete closure; in patients older than 36 weeks there was no response. The data suggest an age-related mechanism for PDA closure and that treatment with indomethacin before 33 weeks of age is probably required. A role for prostaglandin in ductal patency is postulated.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 724314

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  19 in total

1.  Usefulness of indomethacin for patent ductus arteriosus in full-term infants.

Authors:  Takeshi Takami; Hitoshi Yoda; Tadashi Kawakami; Hideshi Yamamura; Toshio Nakanishi; Makoto Nakazawa; Yukito Takei; Tasuku Miyajima; Akinori Hoshika
Journal:  Pediatr Cardiol       Date:  2007-01-02       Impact factor: 1.655

2.  Indomethacin-Responsive Patent Ductus Arteriosus in an Extremely Preterm Infant at 8 Weeks Postnatal Age.

Authors:  Amitoj Singh Chhina; Bharat Kumar Sharma; Malathi Raja; Mohit Singhal; Arvind Shenoi
Journal:  Indian J Pediatr       Date:  2015-02-03       Impact factor: 1.967

3.  Neonatal pharmacology--a practical approach.

Authors:  D A MacKintosh
Journal:  Indian J Pediatr       Date:  1986 Jan-Feb       Impact factor: 1.967

4.  Patent ductus arteriosus in premature babies.

Authors:  M L Chiswick
Journal:  Br Med J (Clin Res Ed)       Date:  1981-12-05

Review 5.  Patent ductus arteriosus: current clinical status.

Authors:  J A Kitterman
Journal:  Arch Dis Child       Date:  1980-02       Impact factor: 3.791

6.  Indomethacin in closure of patent ductus arteriosus.

Authors:  V V Vedanarayanan; I C Verma
Journal:  Indian J Pediatr       Date:  1981 Jul-Aug       Impact factor: 1.967

7.  Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study.

Authors:  J M Smyth; P S Collier; M Darwish; J S Millership; H L Halliday; S Petersen; J C McElnay
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

8.  Patent ductus arteriosus in infants of low birth weight.

Authors:  D R Smith; D H Cook; T Izukawa; P M Olley; P R Swyer; R D Rowe
Journal:  Can Med Assoc J       Date:  1980-10-18       Impact factor: 8.262

9.  Indomethacin use for the management of patent ductus arteriosus in preterms: a web-based survey of practice attitudes among neonatal fellowship program directors in the United States.

Authors:  S B Amin; C Handley; O Carter-Pokras
Journal:  Pediatr Cardiol       Date:  2007-04-24       Impact factor: 1.655

10.  Patent ductus arteriosus in premature infants: a review of current management.

Authors:  W A Neal; M D Mullett
Journal:  Pediatr Cardiol       Date:  1982       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.